Toll-like receptor 2 activation by β2→1-fructans protects barrier function of t84 human intestinal epithelial cells in a chain length-dependent manner

Journal of Nutrition

Volumn 144, Issue 7, 2014, Pages 1002-1008

  Vogt, Leonie M ^a   Meyer, Diederick ^b   Pullens, Gerdie ^c   Faas, Marijke M ^a   Venema, Koen ^d,f   Ramasamy, Uttara ^e   Schols, Henk A ^e   de Vos, Paul ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Sensus   (Netherlands)

^c Cosun Food Technology Centre ^*  (Netherlands)

^d TNO   (Netherlands)

^e WAGENINGEN UNIVERSITY   (Netherlands)

^f Beneficial Microbes Consultancy   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; INULINASE; PHORBOL 13 ACETATE 12 MYRISTATE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SHORT CHAIN FATTY ACID; TOLL LIKE RECEPTOR 2;

ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CELL INTERACTION; CELL PROTECTION; COLON CARCINOMA; DIETARY FIBER; ELECTRIC CELL SUBSTRATE IMPEDANCE SENSING; ELECTRIC RESISTANCE; ENZYME ACTIVATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IMPEDANCE; INTESTINE EPITHELIUM CELL; INTESTINE FUNCTION; PERMEABILITY BARRIER; REGULATORY MECHANISM; TIGHT JUNCTION; TRANSEPITHELIAL ELECTRICAL RESISTANCE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, BLOCKING; CELL LINE; COLON; DIGLYCERIDES; FRUCTANS; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; KIDNEY; LIGANDS; MEMBRANE TRANSPORT MODULATORS; MOLECULAR STRUCTURE; NF-KAPPA B; OLIGOPEPTIDES; PREBIOTICS; PROTECTIVE AGENTS; RECOMBINANT PROTEINS; TETRADECANOYLPHORBOL ACETATE; TIGHT JUNCTIONS; TOLL-LIKE RECEPTOR 2; TRANSCRIPTION FACTOR AP-1;

EID: 84904644804     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.114.191643     Document Type: Article

References (69)

1. Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, Norat T. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ 2011;343:d6617.
2. Fardet A. New hypotheses for the health-protective mechanisms of wholegrain cereals: what is beyond fibre? Nutr Res Rev 2010;23:65-134.
3. Pereira MA, O'Reilly E, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, Hallmans G, Knekt P, Liu S, Pietinen P, et al. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Arch Intern Med 2004;164:370-6.
4. Schulze MB, Schulz M, Heidemann C, Schienkiewitz A, Hoffmann K, Boeing H. Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. Arch Intern Med 2007;167:956-65.
5. Chuang SC, Norat T, Murphy N, Olsen A, Tjonneland A, Overvad K, Boutron-Ruault MC, Perquier F, Dartois L, Kaaks R, et al. Fiber intake and total and cause-specific mortality in the European Prospective Investigation into Cancer and Nutrition cohort. Am J Clin Nutr 2012;96:164-74.
6. Jacobs DR Jr, Andersen LF, Blomhoff R. Whole-grain consumption is associated with a reduced risk of noncardiovascular, noncancer death attributed to inflammatory diseases in the Iowa Women's Health Study. Am J Clin Nutr 2007;85:1606-14.
7. Landberg R. Dietary fiber and mortality: convincing observations that call for mechanistic investigations. Am J Clin Nutr 2012;96:3-4.
8. Park Y, Subar AF, Hollenbeck A, Schatzkin A. Dietary fiber intake and mortality in the NIH-AARP diet and health study. Arch Intern Med 2011;171:1061-8.
9. Meijer K, de Vos P, Priebe MG. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? Curr Opin Clin Nutr Metab Care 2010;13:715-21.
10. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010;104(Suppl 2):S1- 63.
11. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011;3:858-76.
12. Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SY, Gordon S. Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 2002;196:407-12.
13. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999; 401:811-5.
14. Underhill DM, Rossnagle E, Lowell CA, Simmons RM. Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood 2005;106:2543-50.
15. Vogt L, Ramasamy U, Meyer D, Pullens G, Venema K, Faas MM, Schols HA, de Vos P. Immune modulation by different types of beta /1-fructans is toll-like receptor dependent. PLoS ONE. 2013;8:e68367.
16. Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol 2012;30:149-73.
17. Iemoli E, Trabattoni D, Parisotto S, Borgonovo L, Toscano M, Rizzardini G, Clerici M, Ricci E, Fusi A, De Vecchi E, et al. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. J Clin Gastroenterol 2012;46: Suppl:S33-40.
18. Penders J, Stobberingh EE, van den Brandt PA, Thijs C. The role of the intestinal microbiota in the development of atopic disorders. Allergy 2007;62:1223-36.
19. Benard A, Desreumeaux P, Huglo D, Hoorelbeke A, Tonnel AB, Wallaert B. Increased intestinal permeability in bronchial asthma. J Allergy Clin Immunol 1996;97:1173-8.
20. Hijazi Z, Molla AM, Al-Habashi H, Muawad WM, Molla AM, Sharma PN. Intestinal permeability is increased in bronchial asthma. Arch Dis Child 2004;89:227-9.
21. Gassler N, Rohr C, Schneider A, Kartenbeck J, Bach A, Obermuller N, Otto HF, Autschbach F. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol 2001;281:G216-28.
22. Sö derholm JD, Peterson KH, Olaison G, Franzen LE, Westrom B, Magnusson KE, Sjodahl R. Epithelial permeability to proteins in the noninflamed ileum of Crohn's disease? Gastroenterology 1999;117: 65-72.
23. Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, Piemonti L, Pastore MR, Paroni R. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 2006;49: 2824-7.
24. Sapone A, de Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, Lampis R, Kryszak D, Carteni M, Generoso M, et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 2006;55:1443-9.
25. Vaarala O, Atkinson MA, Neu J. The "perfect storm"for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 2008;57:2555-62.
26. Boroni Moreira AP, Fiche Salles Teixeira T, do C Gouveia Peluzio M, de Cassia Goncalves Alfenas R. Gut microbiota and the development of obesity. Nutr Hosp 2012;27:1408-14.
27. Fasano A. Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol 2012;42:71-8.
28. Montalto M, Cuoco L, Ricci R, Maggiano N, Vecchio FM, Gasbarrini G. Immunohistochemical analysis of ZO-1 in the duodenal mucosa of patients with untreated and treated celiac disease. Digestion 2002;65: 227-33.
29. Schulzke JD, Bentzel CJ, Schulzke I, Riecken EO, Fromm M. Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. Pediatr Res 1998;43:435-41.
30. Vogelsang H,Wyatt J, Penner E, Lochs H. Screening for celiac disease in first-degree relatives of patients with celiac disease by lactulose/ mannitol test. Am J Gastroenterol 1995;90:1838-42.
31. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC. Abnormal intestinal permeability in subgroups of diarrheapredominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94.
32. Lee H, Park JH, Park DI, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Chae SW. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome. J Neurogastroenterol Motil 2013;19:244-50.
33. Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr 2005;94:386-93.
34. Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes 2014;5:3-17.
35. Ruutu M, Thomas G, Steck R, Degli-Esposti MA, Zinkernagel MS, Alexander K, Velasco J, Strutton G, Tran A, Benham H, et al. beta-Glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice. Arthritis Rheum 2012;64:2211-22.
36. Seo YS, Shah VH. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol 2012;18:337-46.
37. Albers R, Antoine JM, Bourdet-Sicard R, Calder PC, Gleeson M, Lesourd B, Samartin S, Sanderson IR, Van Loo J, Vas Dias FW, et al. Markers to measure immunomodulation in human nutrition intervention studies. Br J Nutr 2005;94:452-81.
38. de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 2008;111:1-66.
39. Kelly G. Inulin-type prebiotics: a review. (Part 2). Altern Med Rev 2009;14:36-55.
40. Rijnierse A, Jeurink PV, Garssen J, Knippels LM. Food-derived oligosaccharides exhibit pharmaceutical properties. Eur J Pharmacol 2011;688(Suppl 1):S117-23.
41. Vogt LM, Meyer D, Pullens G, Faas MM, Smelt MJ, Venema K, Ramasamy U, Schols HA, de Vos P. Immunological properties of inulintype fructans. Crit Rev Food Sci Nutr 2013;Aug 25 (Epub ahead of print; DOI:10.1080/10408398.2012.656772).
42. Eiwegger T, Stahl B, Haidl P, Schmitt J, Boehm G, Dehlink E, Urbanek R, Szepfalusi Z. Prebiotic oligosaccharides: in vitro evidence for gastrointestinal epithelial transfer and immunomodulatory properties. Pediatr Allergy Immunol 2010;21:1179-88.
43. Cario E. Barrier-protective function of intestinal epithelial Toll-like receptor 2. Mucosal Immunol 2008;1(Suppl 1):S62-6.
44. 2+: a protein kinase C effect. J Membr Biol 1996;149:71-9.
45. Marcon MA, McCool D, Forstner J, Forstner G. Inhibition of mucin secretion in a colonic adenocarcinoma cell line by DIDS and potassium channel blockers. Biochim Biophys Acta 1990;1052:17-23.
46. Lo CM, Keese CR, Giaever I. Impedance analysis ofMDCK cells measured by electric cell-substrate impedance sensing. Biophys J 1995;69:2800-7.
47. Karczewski J, Troost FJ, Konings I, Dekker J, Kleerebezem M, Brummer RJ, Wells JM. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 2010;298:G851-9.
48. Lu C, Liu L, Chen Y, Ha T, Kelley J, Schweitzer J, Kalbfleisch JH, Kao RL, Williams DL, Li C. TLR2 ligand induces protection against cerebral ischemia/reperfusion injury via activation of phosphoinositide 3-kinase/ Akt signaling. J Immunol 2011;187:1458-66.
49. Yuki T, Yoshida H, Akazawa Y, Komiya A, Sugiyama Y, Inoue S. Activation of TLR2 enhances tight junction barrier in epidermal keratinocytes. J Immunol 2011;187:3230-7.
50. Ito H, Takemura N, Sonoyama K, Kawagishi H, Topping DL, Conlon MA, Morita T. Degree of polymerization of inulin-type fructans differentially affects number of lactic acid bacteria, intestinal immune functions, and immunoglobulin A secretion in the rat cecum. J Agric Food Chem 2011;59:5771-8.
51. Ito H, Tanabe H, Kawagishi H, Tadashi W, Yasuhiko T, Sugiyama K, Kiriyama S, Morita T. Short-chain inulin-like fructans reduce endotoxin and bacterial translocations and attenuate development of TNBSinduced colitis in rats. Dig Dis Sci 2009;54:2100-8.
52. Hua F, Ma J, Ha T, Kelley J, Williams DL, Kao RL, Kalbfleisch JH, Browder IW, Li C. Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury. J Neuroimmunol 2008;199:75-82.
53. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007;132:1359-74.
54. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, Aderem A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000;97:13766-71.
55. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, Guiet C, Briere F, Vlach J, Lebecque S, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005;174: 2942-50.
56. van Bergenhenegouwen J, Plantinga TS, Joosten LA, Netea MG, Folkerts G, Kraneveld AD, Garssen J, Vos AP. TLR2 & Co: a critical analysis of the complex interactions between TLR2 and coreceptors. J Leukoc Biol 2013;94:885-902.
57. Visintin A, Latz E, Monks BG, Espevik T, Golenbock DT. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Tolllike receptor-4 aggregation and signal transduction. J Biol Chem 2003;278:48313-20.
58. Murray NR, Davidson LA, Chapkin RS, Clay GustafsonW, Schattenberg DG, Fields AP. Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999;145:699-711.
59. Agbor TA, Demma ZC, Mumy KL, Bien JD, McCormick BA. The ERM protein, ezrin, regulates neutrophil transmigration by modulating the apical localization of MRP2 in response to the SipA effector protein during Salmonella typhimurium infection. Cell Microbiol 2011; 13:2007-21.
60. Koo HN, Hong SH, Seo HG, Yoo TS, Lee KN, Kim NS, Kim CH, Kim HM. Inulin stimulates NO synthesis via activation of PKC-alpha and protein tyrosine kinase, resulting in the activation of NF-kappaB by IFNgamma-primed RAW 264.7 cells. J Nutr Biochem 2003;14:598-605.
61. Farhadi A, Keshavarzian A, Ranjbaran Z, Fields JZ, Banan A. The role of protein kinase C isoforms in modulating injury and repair of the intestinal barrier. J Pharmacol Exp Ther 2006;316:1-7.
62. Pajari AM, Oikarinen S, Grasten S, Mutanen M. Diets enriched with cereal brans or inulin modulate protein kinase C activity and isozyme expression in rat colonic mucosa. Br J Nutr 2000;84:635-43.
63. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 2012;11:937-57.
64. Coussens L, Parker PJ, Rhee L, Yang-Feng TL, Chen E, Waterfield MD, Francke U, Ullrich A. Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. Science 1986;233:859-66.
65. Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y. The structure, expression, and properties of additional members of the protein kinase C family. J Biol Chem 1988;263:6927-32.
66. Ono Y, Kikkawa U, Ogita K, Fujii T, Kurokawa T, Asaoka Y, Sekiguchi K, Ase K, Igarashi K, Nishizuka Y. Expression and properties of two types of protein kinase C: alternative splicing from a single gene. Science 1987;236:1116-20.
67. Parker PJ, Coussens L, Totty N, Rhee L, Young S, Chen E, Stabel S, Waterfield MD, Ullrich A. The complete primary structure of protein kinase C-the major phorbol ester receptor. Science 1986;233:853-9.
68. Song JC, Hanson CM, Tsai V, Farokhzad OC, Lotz M, Matthews JB. Regulation of epithelial transport and barrier function by distinct protein kinase C isoforms. Am J Physiol Cell Physiol 2001;281:C649-61.
69. Langlet C, Springael C, Johnson J, Thomas S, Flamand V, Leitges M, Goldman M, Aksoy E, Willems F. PKC-alpha controls MYD88-dependent TLR/IL-1R signaling and cytokine production in mouse and human dendritic cells. Eur J Immunol 2010;40:505-15.